Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano sits in the upper half of US sponsors by registered trial count (#4,885 of 15,742 sponsors by registered trial count).
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano: 2 sponsored US clinical trials, 2 recruiting.
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano sponsors 2 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting. The most-studied condition in this pipeline is Lung Cancer, Non-Small Cell, with 1 trials.
Mid-pack sponsor footprint
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano is in the upper half of sponsors by trial count (#4,885 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.
Open and recent trials
2 total, page 1 of 1
Therapeutic Areas
What is open in the Fondazione IRCCS Istituto Nazionale dei Tumori, Milano pipeline
2 recruiting of 2 indexed (100% open).
Phase labels are sparse on this sponsor index, so phase mix is not charted here.
Top condition: Lung Cancer, Non-Small Cell (1 trial), 4 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano: open-pipeline peers nationwide
Peers matched on 2 registered trials and 100% open enrollment, not the therapeutic-area sidebar.
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 2 trials (± recruiting share)
- 1200 Pharma · 2 trials · 50% recruiting
- 1ST Biotherapeutics · 2 trials · 50% recruiting
- 3 Waves Wellness · 2 trials · 0% recruiting
- 3EO Health · 2 trials · 0% recruiting
Sponsors near 100% open enrollment (± trial volume)
- AAVantgarde Bio Srl · 100% recruiting · 2 trials
- Acorn Biolabs · 100% recruiting · 3 trials
- Acrivon Therapeutics · 100% recruiting · 2 trials
- ADARx Pharmaceuticals · 100% recruiting · 4 trials
Related
What to do with this Fondazione IRCCS Istituto Nazionale dei Tumori, Milano page
2 registered trials is a research-attention snapshot, not an endorsement of Fondazione IRCCS Istituto Nazionale dei Tumori, Milano or any single study.
- 2 of Fondazione IRCCS Istituto Nazionale dei Tumori, Milano's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Lung Cancer, Non-Small Cell is the condition Fondazione IRCCS Istituto Nazionale dei Tumori, Milano studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Lung Cancer, Non-Small Cell trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Fondazione IRCCS Istituto Nazionale dei Tumori, Milano pipeline card: 2 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.